ATE269698T1 - Transdermale östrogen agonist-antagonist therapie - Google Patents

Transdermale östrogen agonist-antagonist therapie

Info

Publication number
ATE269698T1
ATE269698T1 AT00304611T AT00304611T ATE269698T1 AT E269698 T1 ATE269698 T1 AT E269698T1 AT 00304611 T AT00304611 T AT 00304611T AT 00304611 T AT00304611 T AT 00304611T AT E269698 T1 ATE269698 T1 AT E269698T1
Authority
AT
Austria
Prior art keywords
estrogen agonist
antagonist therapy
transdermal estrogen
transdermal
estrogen
Prior art date
Application number
AT00304611T
Other languages
English (en)
Inventor
Silva-Jardine Paul Andrew Da
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE269698T1 publication Critical patent/ATE269698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
AT00304611T 1999-06-01 2000-05-30 Transdermale östrogen agonist-antagonist therapie ATE269698T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13716499P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
ATE269698T1 true ATE269698T1 (de) 2004-07-15

Family

ID=22476088

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00304611T ATE269698T1 (de) 1999-06-01 2000-05-30 Transdermale östrogen agonist-antagonist therapie

Country Status (16)

Country Link
EP (1) EP1057480B1 (de)
JP (1) JP2001002588A (de)
KR (1) KR20010029770A (de)
AT (1) ATE269698T1 (de)
AU (1) AU3781000A (de)
CA (1) CA2310272A1 (de)
CO (1) CO5170459A1 (de)
DE (1) DE60011710T2 (de)
DK (1) DK1057480T3 (de)
ES (1) ES2220346T3 (de)
HU (1) HUP0002085A3 (de)
IL (1) IL136376A0 (de)
NZ (1) NZ504868A (de)
PE (1) PE20010207A1 (de)
PT (1) PT1057480E (de)
ZA (1) ZA200002693B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
BR0106680A (pt) * 2000-06-01 2002-04-30 Watson Pharmaceuticals Inc Liberação transdermal de lasofoxifeno
US9510946B2 (en) 2012-09-06 2016-12-06 Edwards Lifesciences Corporation Heart valve sealing devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
CO5170459A1 (es) 2002-06-27
ES2220346T3 (es) 2004-12-16
CA2310272A1 (en) 2000-12-01
DK1057480T3 (da) 2004-11-08
PT1057480E (pt) 2004-10-29
HU0002085D0 (en) 2000-08-28
JP2001002588A (ja) 2001-01-09
ZA200002693B (en) 2001-11-30
HUP0002085A2 (en) 2001-03-28
PE20010207A1 (es) 2001-02-28
IL136376A0 (en) 2001-06-14
DE60011710T2 (de) 2005-06-30
EP1057480A2 (de) 2000-12-06
KR20010029770A (ko) 2001-04-16
EP1057480A3 (de) 2002-01-09
EP1057480B1 (de) 2004-06-23
AU3781000A (en) 2000-12-07
HUP0002085A3 (en) 2002-09-30
NZ504868A (en) 2001-09-28
DE60011710D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
GR3035774T3 (en) Substituted benzolactam compounds as substance p antagonists
SE0002286D0 (sv) Compositions and method for protecting skin from UV induced immunosuppression and skin damage
TR200001522T2 (tr) Lipoprotein oksidasyonunun inhibisyonu.
ZA955466B (en) Stereochemical wortmannin derivatives
DE69828042D1 (de) Verfahren und zusammensetzung zur behandlung von krebs
EP1039887A4 (de) Verfahren zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität mit aminothiolverbindungen
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
PT938326E (pt) Fosfopeptidos de sintese para o tratamento de doencas dos ossos
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
TR200102515T2 (tr) Egzersiz kaynaklı astma tedavisi için metod.
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
FI991220A (fi) Menetelmä massan käsittelemiseksi
HK1040184A1 (zh) 治療青光眼之組合療法
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
ATE288303T1 (de) Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
ATE269698T1 (de) Transdermale östrogen agonist-antagonist therapie
NO20014222L (no) Fremgangsmåte for behandling av COPD
ZA9810215B (en) 2-Aryl-3-Aroylbenzo[b]thiophenes useful for the treatment of estrogen deprivation syndrome.
DK1131073T3 (da) Anvendelse af staurosporinderivater til behandling af okulære neovaskulære sygdomme
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
DE60025705D1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
DE69706195T2 (de) Antikonvulsive derivate zur behandlung von psoriasis
FI990127A0 (fi) Menetelmä massan käsittelemiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1057480

Country of ref document: EP

REN Ceased due to non-payment of the annual fee